XII Medical

XII Medical operates at the intersection of medical devices, sleep medicine, and neuromodulation, targeting obstructive sleep apnea with a minimally invasive outpatient approach. Its stated focus differentiates it from conventional continuous positive airway pressure providers by emphasizing an implantable or therapeutic-device pathway rather than an external nighttime breathing system. The company also sits in a competitive field that includes established implantable sleep-apnea specialists such as Inspire Medical Systems and emerging neuromodulation developers such as Nyxoah. However, the available profile does not provide enough product, regulatory, clinical, or commercial detail to determine how XII Medical’s technology compares with those companies on efficacy, implantation method, patient selection, or reimbursement. Its $75 million in disclosed funding, including a $45 million Series B, places it beyond an initial concept-financing stage and supports continued device and clinical development. Investor participation from medical-focused groups and Cleveland Clinic suggests institutional interest in the clinical pathway, while the company’s patent activity spans sleep-disordered breathing, implantable power, and treatment-efficacy evaluation.

XII Medical’s trajectory shows a progression from formation in 2017 to substantial device-development financing. The company raised $30 million in Series A funding on May 5, 2022, then increased its disclosed capital base to $75 million with a $45 million Series B on Aug 21, 2024. The later round added Omega Funds as lead investor and included strategic and healthcare-oriented participants such as Cleveland Clinic and Intuitive Ventures. The company’s employee profile is consistent with a focused medical-device organization of approximately 11 to 50 people. Garrett Schwab became President and CEO in May 2021, followed by quality and regulatory leadership from Judy Brimacombe and software leadership from Bhavesh Patel in late 2021; Anthony Caparso has led technology since June 2019. Patent publications across 2024 broadened the apparent technical scope from sleep-disordered-breathing devices to implantable power and efficacy evaluation. There is no disclosed hiring plan, revenue data, product-launch history, or evidence of a completed regulatory approval, so the next growth inflection points remain uncertain.